|

GTAEXS617 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: REC-617

Pipeline

Phase 1/2: 1

Top Sponsors

  • Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1

Indications

  • Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma1
  • Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)1
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Triple Negative Breast Cancer (TNBC)1
  • Non-small Cell Lung Cancer (NSCLC)1

Grand Rapids, Michigan1 trial

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

START Midwest

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.